This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Knapp, L. E. Articles by Kugler, A. R. Search for Related Content PubMed PubMed Citation Articles by Knapp, L. E. Articles by Kugler, A. R. Social Bookmarking                         What's this?

Clinical Experience With Fosphenytoin in Adults: Pharmacokinetics, Safety, and Efficacy

CNS Clinical Development Department, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert, Company, Ann Arbor, MI

Alan R. Kugler, PhD

Pharmacokinetics, Pharmacodynamics, and Metabolism Department Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI

Fosphenytoin, a prodrug of phenytoin, is rapidly and completely converted to phenytoin in adults after intravenous or intramuscular administration and is significantly better tolerated than parenteral phenytoin. Fosphenytoin is highly plasma-protein bound and, when present in sufficient concentration, will displace phenytoin from plasma proteins. The clinical utility is that fosphenytoin may be used to achieve therapeutic phenytoin concentrations more rapidly than intravenous phenytoin infused at its maximum recommended rate. In a clinical study of generalized convulsive status epilepticus, fosphenytoin, with or without benzodiazepine pretreatment, controlled seizures in 76 (93.8%) of 81 patients. In other studies, fosphenytoin maintained seizure control when substituted for oral phenytoin and for seizure prophylaxis in neurosurgery and trauma patients. Adverse events associated with fosphenytoin generally were related to the central nervous system and were similar to those associated with phenytoin, except for a higher incidence of transient pruritus with fosphenytoin. Intravenous fosphenytoin has significant advantages over intravenous phenytoin: It requires a shorter infusion time and fewer intravenous disruptions, causes less pain and burning at the infusion site and minimal consequences in case of intravenous infiltration, allows longer maintenance of intravenous sites, and has better intravenous fluid compatibility and stability. In contrast to intramuscular phenytoin, intramuscular fosphenytoin is well tolerated in both large loading doses and maintenance doses. (J Child Neurol 1998;13(Suppl 1):S15-S18).

Journal of Child Neurology, Vol. 13, No. 1 Suppl, S15-S18 (1998)
DOI: 10.1177/0883073898013001051


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?